$EDSA - Pharma8k's

12 Dec 2025 SEC Filing 8-K $EDSA

Edesa Biotech (EDSA) Reports Phase 3 Success for ARDS Drug, $7.2M FY2025 Loss

Edesa Biotech (EDSA) disclosed Phase 3 success for paridiprubart in ARDS and a $7.2M net loss for FY2025 in an 8-K filing.